Español 
English
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Artículos Relacionados
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. VER MÁS
-
UDIBI
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. VER MÁS
-
UDIBI
The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. VER...
-
UDIBI
Fecha de publicación: 6 de octubre de 2021 Increased survival in puppies affected by Canine Parvovirus type II using...
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
-
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). VER MÁS
